Scynexis’ oral antifungal leads to clinical benefit rate of 85%

Scynexis Inc. (NASDAQ:SCYX) reported interim data from the first 20 patients who were treated in the single-arm Phase III FURI trial to treat refractory mucocutaneous and invasive fungal infections showing that oral ibrexafungerp (formerly

Read the full 348 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE